Politics · India Bureau
Novartis suffers major setback as experimental muscle drug fails trials
Swiss pharmaceutical giant Novartis has encountered its third clinical trial failure in as many days, with its experimental muscle disorder treatment del-desiran falling short of efficacy targets. The failure represents a significant blow to the company's $12 billion acquisition of Avidity Biosciences, where the drug was positioned as a potential blockbuster therapy.
LSN India ·
Novartis announced that del-desiran, a muscle-targeting medicine developed through the company's high-profile takeover of Avidity Biosciences, has failed to meet primary endpoints in clinical testing. The setback marks the latest in a troubling sequence of trial disappointments for the Swiss drugmaker within a compressed timeframe, raising fresh questions about the company's pipeline strength and research direction.
The del-desiran program represented a cornerstone rationale for Novartis's $12 billion acquisition of Avidity, a US-based biotech firm specializing in muscle disorders. The drug had been widely anticipated within the pharmaceutical industry as a potential blockbuster therapy with significant commercial potential, making the trial failure particularly consequential for shareholder confidence and the company's near-term revenue outlook.
The failure adds to mounting pressure on Novartis leadership as multiple development programs face critical junctures. The company has not immediately disclosed details regarding next steps for del-desiran or whether additional trials may be pursued, though observers expect management to provide strategic guidance during upcoming investor communications.
The setback underscores the inherent risks in large pharmaceutical acquisitions, particularly when valuations are heavily weighted toward unproven drug candidates. Industry analysts are likely to reassess Novartis's acquisition strategy and pipeline valuations in coming days.